Fat-Dissolving Injections

What it is

Injection lipolysis is a class of non-surgical procedures in which adipocytolytic or lipolytic agents are injected directly into subcutaneous fat to reduce the number of fat cells in a targeted area.

The most studied agent is deoxycholic acid (DCA), an endogenous secondary bile acid that disrupts adipocyte plasma membrane integrity through a detergent-like mechanism, triggering an inflammatory cleanup response and downstream fibroblast activation. Phosphatidylcholine combined with sodium deoxycholate (the historical "Lipodissolve" formulation) is a surfactant-assisted alternative; the FDA and EMA have warned against PPC/DC products for injection.

V-Olet (브이올렛), the Korean domestic DCA injectable, received MFDS approval in October 2021 for submental fat. LG Chem's Bellacolin (벨라콜린) is a Korean PPC-based MFDS-approved alternative. Carboxytherapy (카복시) is a separate procedure entirely: medical-grade CO2 gas is infused subcutaneously to trigger the Bohr effect, increasing local blood flow and oxygen delivery, with secondary effects on lymphatic drainage and collagen synthesis. It is widely offered at Korean clinics for skin and cellulite indications, not chemical lipolysis.

How it works

DCA injected at 2 mg/cm² in 0.2 mL aliquots at 1 cm grid intervals causes immediate adipocyte membrane disruption. Macrophages clear cellular debris over days 3 to 14. Fibroblast activation and collagen deposition follow by day 28. Because fat cells are destroyed rather than shrunk, results are durable when weight remains stable. Albumin in non-adipocyte tissues preferentially binds DCA, inactivating it before it can damage skin, muscle, or nerve at standard concentrations.

V-Olet demonstrated at least one grade improvement in submental fat reduction in 71.6 percent of patients in clinical trials. Carboxytherapy operates through a different mechanism (gas-induced perfusion), not adipocyte destruction, and is grouped here because Korean clinics cluster both under the 지방분해주사 umbrella in marketing.

Origin and development

Kythera Biopharmaceuticals developed ATX-101 (deoxycholic acid). FDA approved Kybella on April 29, 2015 (NDA 206333) as the first injectable fat-dissolving drug, indicated for submental fat reduction in adults. Kybella was imported and distributed in South Korea as "Belkyra" by Daewoong Pharmaceutical beginning in 2021. V-Olet received MFDS approval in October 2021 as the first Korean-manufactured DCA injectable specifically approved for submental fat.

A separate market exists for unapproved products. The FDA's December 2023 warning specifically named Aqualyx, Lipodissolve, Lipo Lab, and Kabelline as unapproved fat-dissolving injections, citing serious adverse events including permanent scars, serious infections, skin deformities, cysts, and deep painful knots. These products remain available through unlicensed distributors and are not FDA-approved.

Regulatory status

Typical protocol

• Kybella / V-Olet (submental, approved indication): DCA at 2 mg/cm² in 0.2 mL aliquots at 1 cm grid intervals. 2 to 6 sessions spaced at least 1 month apart. Procedure under 20 minutes. Topical lidocaine and cold packs for anesthesia. Significant chin and jawline swelling for 2 to 7 days. Results visible at 4 to 8 weeks.
• Off-label body lipolysis: 5 to 10 sessions at 2 to 4 week intervals. No standardized protocol; carries elevated risk of non-selective tissue damage, infection, and scarring.
• Carboxytherapy (카복시): medical-grade CO2 infusion via fine needle, approximately 2 minutes per session, typically twice weekly. Common in Korean obesity-clinic packages.

Commonly reported effects

FDA Phase III pivotal trial data for Kybella (n=513 treated) reported the following injection-site reactions: any reaction 96 percent, edema or swelling 87 percent, hematoma or bruising 72 percent, pain 70 percent, numbness approximately 65 percent, induration approximately 33 percent. Marginal mandibular nerve paresis occurred in 4 percent of treated persons, presenting as asymmetric smile or facial weakness. All cases in the REFINE trials were mild to moderate and fully resolved, with median duration of 44 days and range 1 to 298 days.

A 2024 Plastic and Reconstructive Surgery Global Open case report described extensive peripheral nerve injury after Kybella injection, attributed to direct axonal toxicity rather than myelin damage. Unapproved products (Lipo Lab, Kabelline) are associated with permanent scars, serious infections, skin deformities, cysts, and deep painful knots per FDA warning data. Carboxytherapy adverse events are mild and transient: brief pressure during injection, temporary subcutaneous emphysema, occasional bruising.

Korea vs US availability

Per a 모두닥 (Modoodoc) January 2026 survey of 228 clinics, 지방분해주사 averages ₩173,402 per area, with minimums around ₩3,300 and maximums up to ₩600,000. V-Olet for submental fat is widely available in Gangnam at approximately ₩150,000 to ₩300,000 per session. Carboxytherapy runs ₩30,000 to ₩80,000 per session at specialty clinics.

In the United States, Kybella costs approximately $1,200 to $1,800 per session, with 2 to 6 sessions typically required for a total treatment course of roughly $2,400 to $10,800. No other FDA-approved fat-dissolving injectable exists for any body indication. Korean fat-dissolving products other than Kybella/Belkyra are not available through legal US clinical channels.

What to research before

• Confirm what is in the syringe. "지방분해주사" covers approved DCA products, MFDS-approved PPC products, and unapproved imports. The risk profile differs substantially.
• Approved vs off-label area. Kybella and V-Olet are approved for submental fat. Use on body areas (flanks, arms, abdomen) is off-label and carries elevated risk of non-selective tissue damage.
• Avoid clinics offering Lipo Lab or Kabelline. Both are FDA-warned products linked to permanent scars, serious infections, and deep painful knots. Korean clinics may carry them through unlicensed distribution.
• Verify operator credentials. Marginal mandibular nerve paresis risk in submental injection is anatomy-dependent. Our credential verification guide covers KSPRS and dermatology specialty registries.
• See also: our Korean Surgery Safety Guide.

Related procedures

• Liposuction — surgical alternative for larger volumes of fat
• Cryolipolysis (CoolSculpting) — non-injection fat reduction
• HIFU body cartridges (Shurink Universe 6.0–13.0 mm) — energy-based alternative
• Carboxytherapy — gas-based companion procedure, often paired with chemical lipolysis

Sources

1. FDA. Using Fat-Dissolving Injections That Are Not FDA Approved Can Be Harmful. December 20, 2023. https://www.fda.gov/drugs/buying-using-medicine-safely/using-fat-dissolving-injections-are-not-fda-approved-can-be-harmful
2. FDA NDA Review for Kybella (deoxycholic acid). NDA 206333. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/206333Orig1s000ODMemo.pdf
3. Toxnfill Global. V-OLET product page. https://eng.toxnfill.com/m/brand/detail.php?c=3704&i=23122
4. PMC / Plastic and Reconstructive Surgery Global Open. Peripheral Nerve Injury After Deoxycholic Acid Injection. April 2024. https://pmc.ncbi.nlm.nih.gov/articles/PMC11041137/
5. 365mc Global. Carboxytherapy Korea. https://365mcglobal.com/all-treatments/carboxytherapy/
6. 여성조선 (Yeosungjoseon). Medical tourism dermatology trend feature. August 2024. https://woman.chosun.com/news/articleView.html?idxno=117230
7. 모두닥 (Modoodoc) blog. 지방분해주사 228개 병원 평균가. January 2026. https://www.modoodoc.com/blog/post/130/
8. ASPS 2023 Cosmetic Procedures Average Cost. https://www.plasticsurgery.org/Documents/News/Statistics/2023/cosmetic-procedures-average-cost-2023.pdf